Cycloplegia

Summary

Cycloplegia (MONDO:0005555) is a disease and 4 clinical trials. Top therapeutic interventions include cyclopentolate and tropicamide. A subtype of eye accommodation disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cycloplegia
Mondo ID	MONDO:0005555
EFO	EFO:0005758
DOID	DOID:10033
ICD-10-CM	H52.52
SNOMED CT	68158006
UMLS	C0235238
MedGen	536368
Is cancer (heuristic)	no

Also known as: paresis of accommodation

Disease family

This is a subtype of eye accommodation disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › eye accommodation disease › cycloplegia

Related subtypes (3): total internal ophthalmoplegia, accommodative spasm, presbyopia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	3
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05442801	PHASE4	COMPLETED	Cycloplegic Refraction Among Children
NCT05449015	PHASE4	UNKNOWN	Study on the Effect of Two Ways of Cycloplegia on Biological Parameters of Ciliary Muscle
NCT06077682	PHASE4	UNKNOWN	Cycloplegic Refraction in Pediatric Patients With Esotropia
NCT05585736	Not specified	COMPLETED	Cycloplegia and Refractive Status

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPENTOLATE	4	2
TROPICAMIDE	4	2
CHEMBL1457550	0	2